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Abstract
Background: Left ventricular non-compaction (LVNC) is a specific cardiomyopathy that oc-
curs following a disruption of endomyocardial morphogenesis. This study presents clinical fin-
dings, diagnostic features, treatment and follow-up of pediatric patients diagnosed with LVNC.
Methods: Patients with LVNC who were followed from January 2006 to March 2010 were
included in this study. Diagnosis was made with the use of characteristic findings of magnetic
resonance imaging and echocardiography. Holter electrocardiography and metabolic screening
tests were also performed in all patients.
Results: A total of 24 patients were studied (18 male, six female). Patient age at diagnosis
was 50 ± 60 months (eight days to 15 years). Average follow-up period was 22 ± 12 months
(four months to four years). Findings at diagnosis were as follows: eight (33%) patients had
heart failure, five (20%) had rhythm abnormalities, five (20%) had cardiomegaly, two had
murmurs, two had cyanosis, and two presented with fatigue. Ten (41%) patients had been
followed previously with other diagnoses. In 21 (87.5%) patients, electrocardiographic abnor-
malities were noted, especially left ventricular hypertrophy and ST-T changes. Patients had an
average ejection fraction of 46% (18–73%) and three of them had additional congenital heart
disease (patent ductus arteriosus, aortopulmonary window and complex cyanotic heart disease).
Scanning for metabolic diseases revealed fatty acid oxidation disorder in one patient, and
mitochondrial disease in another. During follow-up, a permanent pacemaker was implanted in
a patient with severe bradycardia and ventricular dysfunction, and three patients died.
Conclusion: LVNC can be diagnosed at any age from newborn to adolescent and has
a variable clinical course. Closer study of patients with cardiomegaly and heart failure can
reduce delays in diagnosis of LVNC. (Cardiol J 2011; 18, 2: 176–184)
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Introduction
Left ventricular non-compaction (LVNC) is
a specific cardiomyopathy (CMP) caused by a dis-
ruption in the embryogenesis of the endocardium
and myocardium. Formerly known as ‘spongy myo-
cardium’ it is characterized by trabeculations and
deep intertrabecular recesses in the ventricular myo-
cardium [1–3]. Its frequency has increased and it
has been reported as comprising 9% of all childhood
cardiomyopathies in recent studies [2–4]. It typi-
cally affects the left ventricle (LV) but the right ven-
tricle (RV) can be affected as well [2, 5].
The anatomical structure of this cardiomyo-
pathy can be detected at birth, but may appear at
any age and have variable clinical presentation. De-
terioration of systolic and diastolic functions, con-
gestive heart failure (CHF), thromboembolic
events, supraventricular and ventricular arrhyth-
mias are its major clinical features [2–4, 6–13]. In
the majority of LVNC patients, presence of dys-
morphic facies, growth retardation and neuromus-
cular anomalies, findings of mitochondrial disease
in muscle biopsies and the presence of similar pa-
tients in the family history suggest the possibility
of metabolic disease [3, 8].
While LVNC is generally diagnosed using cer-
tain echocardiographic criteria, cardiac magnetic
resonance imaging (MRI) can also be useful in sus-
pected cases of LVNC and may help determine the
prognosis by detecting fibrosis [14–16].
In this, the largest study of the pediatric po-
pulation with LVNC in our country, we present the
clinical findings at referral, 24-hour Holter elec-
trocardiographic (ECG) findings, treatment and
follow-up of 24 patients with LVNC diagnosed by
echocardiography (ECHO) and cardiac MRI. Due
to the possible  association with metabolic disease,
metabolic screening was done in all patients, while
muscle biopsy and cranial MR were done where
necessary.
Methods
Twenty-four LVNC patients aged between
eight days and 15 years were enrolled in this study
between January 2006 and March 2010. Detailed
histories, previous diagnoses, physical examina-
tions, associated diseases, 12-lead ECGs, chest
X-rays, metabolic disease screenings, 24-hour Holter
ECGs, 2-D, M-mode and color Doppler ECHOs and
cardiac MRIs of 22 patients were recorded. Clini-
cal follow-up, treatment and invasive procedures
were recorded as well.
2-D, M-mode and color Doppler ECHO exam-
inations were evaluated according to the guidelines
of the American Echocardiography Association
[17, 18]. Trabeculations and deep recesses in the LV
myocardium were assessed in the parasternal, api-
cal and subxiphoid views. Left ventricle end-sys-
tolic/diastolic diameters and shortening fraction
were estimated and structural pathologies were also
recorded.
LVNC diagnosis was made after ECHO exami-
nation [14] if:
— there was an increase in segmental LV wall
thickness, and if thin compact epicardial layer
and thick non-compacted endomyocardial layer
were present;
— the ratio of end-systolic non-compacted/com-
pacted myocardium was > 2;
— there were deep intertrabecular recesses com-
municating with ventricular cavities and flow
was detected with color Doppler ECHO in these
areas.
Echocardiographic examinations were done by
three different pediatric cardiologists and the affect-
ed segments were recorded.
Cardiac MRI was performed using a 1.5 T scan-
ner (Symphony, Siemens Medical Systems, Erlan-
gen, Germany). In the test, the myocardium was
divided into nine parts (one apical, four midventri-
cular, four basal) and the diagnosis was made if the
ratio of thick non-compacted myocardial layer to
thin compacted epicardial myocardium layer was
greater than 2.3 at end-diastole.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Statistical analysis
Statistical Package for the Social Science 13.0
for Windows (SPSS, Chicago, IL, USA) was used for
data analysis (reliability, construct validity and inter-
nal consistency). The average values and intervals
were specified as ± SD. Continuous variables were
shown as mean, categorical variables were shown as
percentage or ratio. Our categorical data was com-
pared with data from other studies using Fisher’s
exact test and c2 test (Table 1). Continuous variables
were not compared due to lack of data in other stu-
dies. A p < 0.05 was considered as significant.
Results
General findings and demographic data
LVNC was detected in only 24 out of the 20,000
patients examined echocardiographically over a four
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year period. Eighteen (75%) patients who were
diagnosed with ECHO and cardiac MR were male,
and six (25%) were female. Average age at diagno-
sis was 50 ± 60 months (eight days to 15 years)
and mean follow-up period was 22 ± 12 months (be-
tween four months and four years).
Clinical findings
Ten (41%) out of the 24 patients with LVNC
were less than one year old. Clinical findings of
patients before diagnosis are shown in Table 2. The
main presentation was signs of CHF, seen in eight
(33%) patients. Cyanosis, heart murmurs, fatigue
and weakness were seen less frequently. Cardiome-
galy on chest X-ray in five patients, and ECG ab-
normalities in another five, were the main initial
findings. Eight patients had more than one finding.
Three (12.5%) patients had additional congenital
heart disease. One of them had patent ductus arte-
riosus (PDA) and patent foramen ovale (PFO), an-
other had complex cyanotic congenital heart disease
(tricuspid atresia, atrial septal defect, RV hypopla-
sia, ventricular septal defect and pulmonary artery
hypoplasia), and the third had an aortopulmonary
window and severe pulmonary hypertension. One
patient underwent PDA coil occlusion, and the pa-
tient with complex cyanotic heart disease under-
went a Blalock-Taussig shunt operation.
Associated systemic diseases
and metabolic screening
During the diagnosis and follow-up of patients
with LVNC, in nine (37%) of them additional clinical
findings were observed. Four (16%) patients had dys-
morphic facies, seven (29%) had neurological prob-
lems (including epilepsy, hypotonia, myopathy, ma-
crocephaly, hydrocephaly, and mental/motor retar-
dation), two had urinary system anomalies (renal
atrophy secondary to horseshoe kidney and vesi-
coureteral reflux), and one had congenital adrenal hy-
perplasia. None of them had a family history of LVNC.
Because of the neurological problems and the
reported association between LVNC and metabo-
lic diseases [2], metabolic screening was performed
in all patients. It included arterial blood gas, blood
lactate, pyruvate and ammonia levels, muscle en-
zymes, amino acid and acylcarnitine profiles by tan-
dem mass spectrofotometry, biotidinase screening
and urine examination. Mitochondrial disease was
detected in a patient with hypotonia and mental
motor retardation, and very long chain fatty acid oxi-
dation deficiency was found in a patient with chronic
skeletal muscle myopathy and elevated muscle
enzymes. Four patients with dysmorphic facies
showed normal results of chromosomal analysis. No
other genetic tests were performed.
Table 1. Clinical characteristics of children diagnosed with left ventricular non-compaction.
Characteristics Chin Ichida Pignatelli Tsai Wald Alehan Present P*
et al. [7] et al. [8] et al. [2] et al. [3] et al. [4]  [13]  study
Number of patients 8 27 36 46 22 9 24
Male (%) 63 56 56 50 41 88 75 NS
Age at diagnosis (years) 7 5 0.25 0.44 3.9 7 4.1
Mean follow-up (years) £ 5 6 3.2 1.2 3 ≥ 5 £ 5
Decreased EF (%) 63 48 83 52 77 66 71 NS
ECG abnormalities (%) 88 88 75 80 100 77 87.5 NS
WPW syndrome (%) 13 15 17 7 9 0 4 NS
Ventricular tachycardia (%) 38 0 3 4 14 0 4 0.039**
Heart failure (%) 63 22 39 54 91 56 33 < 0.001***
Systemic embolic events (%) 38 0 0 2 0 0 0 0.01**
Death (%) 38 7 14 20 14 22 12.5 NS
EF — ejection fraction; WPW — Wolff-Parkinson-White; NS — not significant; *our own patient group, compared with other groups as binary;
**our group of patients, and Chin et al. [7] data are compared; ***our group of patients, and Wald et al. [4] data are compared
Table 2. Signs and symptoms of patients at
initial diagnosis.
Signs and symptoms Number of patients
Congestive heart failure 8
Heart murmur 2
Cyanosis 2
Failure to thrive 2
Cardiomegaly on chest X-ray 5
Rhythm disorders and 5
ECG abnormalities
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Electrocardiographic findings
Twenty-one out of the 24 (87.5%) patients with
LVNC showed ECG abnormalities at diagnosis. The
most frequent findings were: LV hypertrophy, ST
depression in DII, III, aVF and V4–V6 leads, and
flattened and inverted T wave. The Wolff-Parkin-
son-White (WPW) pattern was detected on the stan-
dard and Holter ECG of one patient, and hemody-
namically significant bradycardia was seen in three
patients. On the 24-hour Holter ECG, two patients
showed short runs of supraventricular tachycardia
(SVT), and a 15 year-old patient complaining of pal-
pitations had 45 beats of ventricular tachycardia
(VT). Standard ECG and Holter ECG findings were
normal in three (12.5%) patients at diagnosis.
Echocardiographic and cardiac MR findings
The echocardiographic and cardiac MR findings
of patients with LVNC are shown in Table 3. Promi-
nent LV trabeculation and intertrabecular recess-
es communicating with the ventricular cavity were
detected with 2-D echocardiography (Fig. 1) and
cardiac MR in all patients. Although it could not be
seen with 2-D ECHO, RV involvement was ob-
served with cardiac MR in four (16%) patients. None
of our patients had RV involvement solely. Non-
-compaction was more prominent in the myocardial
segment of the LV apex and posterior wall. ECHO
showed the average end-systolic LV ratio of non-
-compacted to compacted myocardium to be 2.5
(2.1–3.5), while cardiac MRI showed the end-dias-
tolic ratio to be 2.8 (2.4–3.5) (Fig. 2). Seventeen
(71%) patients had LV dysfunction at diagnosis.
Average ejection and shortening fractions were 46%
(18–73) and 22% (8–38), respectively. None of
the patients had intracardiac thrombi or embolic
phenomena at diagnosis or during follow-up, but
a 15 year-old patient (patient 15) who was referred
to us with palpitations had been on coumadin for in-
tracardiac thrombi for five years.
When we examined our patients retrospective-
ly, we saw that ten of them (41%) were followed up
with different diagnoses. Six of these ten were fol-
lowed for their cardiac conditions and their diag-
noses were delayed (patients 8, 12, 14, 18, 22, and
23 in Table 3). This delay in diagnosis may be ex-
plained by the similarity between cardiomyopathies
and LVNC, and by a lack of experience in the clini-
cian making the diagnosis. Five of these six patients
were followed with the diagnosis of dilated cardio-
myopathy and one was diagnosed with a double
chambered LV.
Treatment and follow-up
After the diagnosis, CHF was treated as fol-
lows: 15 patients were put on digoxin, 12 patients
were put on furosemide and spironolactone for the
diuretic effect, and 15 patients were put on capto-
pril to reduce the afterload. Two patients with mi-
tochondrial disease and fatty acid oxidation deficien-
cy were treated with a metabolic drug complex (co-
enzyme Q, carnitine, thiamine and medium-chain
fatty acid diet). For CHF, 12 patients were treated
with carvedilol, and an antiaggregant dose of ace-
tylsalicylic acid was started in all patients. None of
the patients had thromboembolic events. During
follow-up, patient 1 (Table 3) had a permanent pace-
maker implanted due to severe bradycardia, exer-
cise intolerance and LV dysfunction, and another
patient was treated with amiodarone for VT found
on his Holter ECG. The other two patients with he-
modynamically significant sinus bradycardia were
diagnosed in the neonatal period. They were treat-
ed with isoproterenol and, since no further brady-
cardia episodes were seen,  no additional interven-
tion was made.
Depending on their clinical condition, patients
were followed-up either every three or six months.
In addition to routine ECG and ECHO exams, 24-hour
Holter ECG was taken if necessary. In two patients
with SVT, and one patient with VT, no relapse was
seen after carvedilol and amiodarone+carvedilol
treatment, respectively. In two patients with LV
dysfunction who underwent treatment with anticon-
gestants and carvedilol, LV ejection fraction rose
above 55% after 15 months. In one patient, signs of
systolic dysfunction increased, despite treatment.
The other 11 patients experienced no improvement
in LV function. None of the seven (29%) patients
whose LV function was normal at diagnosis deve-
loped any ventricular function disorders and none
needed drug treatment. No intracardiac thrombi
were detected during echocardiographic follow-up
in any of the patients.
Average follow-up period was 22 months (be-
tween four months and four years). Of the three
patients who died, one was a 13 year-old on intense
inotropic support who had been diagnosed with
LVNC four years previously, had had dilated cardio-
myopathy for three years and died of severe CHF
and multi-organ failure. A second patient died in the
intensive care unit after an adrenal crisis, severe
metabolic acidosis, hypoglycemia and severe brady-
cardia. The third death was of a patient who had
pulmonary hypertensive crisis and VT within
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24 hours of having an angiography (carried out for
aortopulmonary window and severe pulmonary hy-
pertension and which revealed biventricular non-
-compaction).
Table 3. Echocardiography and cardiac magnetic resonance imaging (MRI) findings at diagnosis*.
Case LVEDD EF (%) SF (%) Non-compacted End-systolic End-diastolic Additional
no. [mm]  (n ≥ 55%)  (n = 29–  segment NC/C NC/C cardiac
–48%) localization (ECHO) (cardiac MRI)   pathology
1 47 (n £ 43) 47 22 LV apex, lateral wall 2.5 3.2 –
2 30 (n £ 31) 69 37 LV apex, posterior wall 3.4 3.5 TA + VSD +
and septum + ASD + RV
hypoplasia,
pulmonary
hypoplasia
3 56 (n £ 40) 21 10 LV apex 2.4 2.5 –
and lateral wall
4 46 (n £ 33) 35 14 LV lateral wall 2.8 3 –
5 30 (n £ 31) 67 35 LV apex and 2.1 2.4 –
posterior wall
6 25 (n £ 30) 70 36 LV posterior wall 2.2 2.5 –
7 51 (n £ 37) 21 10 LV posterior 2.5 3 –
and lateral wall
8 30 (n £ 43) 68 38 LV midventricular 2.5 3.4 –
segment
9 52 (n £ 34) 23 11 LV apex, inferior 2.5 3 –
ventricular septum
10 46 (n £ 37) 38 16 LV apex and posterior 2.4 2.8 –
wall, RV apex
11 33 (n £ 37) 48 24 LV apex and 2.4 2.5 PDA, PFO
 posterior wall
12 39 (n £ 30) 29 14 LV apex and 2.3 2.8 –
 posterior wall
13 24 (n £ 30) 71 36 LV apex 2.2 – –
14 60 (n £ 56) 32 19 LV apex and posterior 3.4 3.5 –
wall, RV apex
15 64 (n £ 54) 48 26 LV apex 2.5 2.5 –
16 27 (n £ 30) 73 38 LV apex and mid 2.2 2.4 –
ventricular segment
17 32 (n £ 30) 39 14 LV apex and lateral wall 3 3.5
18 57 (n £ 47) 18 8 LV apex, midventricular 2.4 2.5 Pericardial
and lateral wall, RV apex effusion
19 33 (n £ 37) 56 29 LV apex and posterior wall 2.2 2.4 –
20 63 (n £ 61) 53 26 LV apex and posterior wall 2.4 3 –
21 58 (n £ 53) 54 26 LV apex and posterior
wall, RV apex 2.3 3.2 Aorticopulmonary
window,
pulmonary
hypertension
22 50 (n £ 56) 50 25 LV mid ventricular 2.2 2.4 –
 segment
23 71 (n £ 56) 28 12 LV apex and 2.3 3.4 –
mid ventricular segment,
lateral wall
24 32 (n £ 29) 48 23 LV apex 3.5 – –
and posterior wall
ASD — atrial septal defect; EF — ejection fraction; SF — shortening fraction; LV — left ventricular; LVEDD — left ventricular end-diastolic diameter;
n — normal value; NC/C — non-compacted segment/compacted segment ratio; PDA — patent ductus arteriosus; PFO — patent foramen ovale;
RV — right ventricle; TA — tricuspid atresia; VSD — ventricular septal defect; *references [19] and [20] were used to evaluate normal left ventricular
measurements.
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Discussion
Today, thanks to improved awareness and ad-
vanced diagnostic tools, LVNC is a congenital car-
diomyopathy that is being diagnosed with increas-
ing frequency [3]. The cause of the disease is
thought to be a disruption of the endomyocardial
morphogenesis at between the fifth and the eighth
gestational week [2, 11]. The isolated form of the
disease is rare and is classified as a genetic cardio-
myopathy by the American Heart Association. It can
coexist with congenital heart diseases, particularly
during childhood [3, 21]. While pediatric studies
report that the most frequently seen concomitant
conditions are ventricular septal defect and LV out-
flow obstructions, LVNC can also be accompanied
by tetralogy of Fallot, bicuspid aortic valve, Ebstein
anomaly and PDA [3, 22–26]. Three (12.5%) of our
patients had concomitant cardiac anomalies and one
of the patients was being followed by an outpatient
clinic due to LV hypertrophy and double chambered
LV caused by mid-cavitary narrowing.
The first choice (and standard procedure) for
diagnosing LVNC is 2-D Doppler echocardiography.
But computed tomography, MRI and angiography
can also be used for diagnosis [2–13]. For an accu-
rate and reliable diagnosis, the physician must be
familiar with the condition and must apply very spe-
cific diagnostic criteria. Despite this, misdiagnoses
may still happen and patients may be followed with
inaccurate diagnoses. LVNC is frequently misdia-
gnosed as dilated cardiomyopathy, hypertrophic car-
diomyopathy, restrictive cardiomyopathy, endomyo-
cardial fibroelastosis and myocarditis [8, 11, 13].
In our study group, six (25%) patients had been mis-
diagnosed. Five had been followed up with a diag-
nosis of dilated cardiomyopathy and one with
a diagnosis of hypertrophic cardiomyopathy and
double chambered LV. Similarly, Alehan [13] re-
ports that in four (44%) of his patients, LVNC was
misdiagnosed as dilated cardiomyopathy.
Figure 2. Cardiac magnetic resonance imaging: A. Non-
-compacted and compacted segment in left ventricular
short-axis view; B. End-diastolic spongeous appearance;
C. End-systolic appearance.
Figure 1. Echocardiographic examination. Trabecula-
tions, non-compacted and compacted segments; LV —
left ventricle.
A
B
C
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Even though RV involvement has been report-
ed in patients with LVNC [2, 5, 27], it is clinically
insignificant and difficult to diagnose with ECHO.
Additional imaging modalities should be used to
prevent a delay in diagnosis and the possible mis-
diagnosis of LVNC, which is a disease with a poor
prognosis. Cardiac MRI has a good correlation with
ECHO and has a high sensitivity and specificity in
detecting non-compacted segments. Thus the chance
of misdiagnosis decreases, and the obtained data on
RV involvement, fibrosis and segmental analysis may
increase [2, 15, 16, 28]. In our study, we performed
cardiac MR in 92% of patients, detecting RV involve-
ment in four (overlooked by ECHO).
Whether congenital heart disease is present or
not, CHF, arrhythmias and thromboembolic events
are the three major clinical presentations of LVNC.
Particularly pediatric studies have shown that car-
diac failure is the most frequent presentation at dia-
gnosis and follow-up, with a prevalence of between
35% and 91% [2, 3, 5, 7–9, 13, 22] (Table 1). In our
study, major clinical manifestations included cardiac
shock in two patients, CHF in six and cardiomega-
ly in five. ECHO revealed LV dysfunction in 71%
of patients. The cause of cardiac failure in patients
with LVNC is unclear, but possible explanations
include a coronary microcirculation disorder lead-
ing to subendocardial ischemia in the non-compac-
ted area. Another possible explanation is depen-
dence of the non-compacted area on aerobic oxida-
tion and its sensitivity to hypoxia and the toxic
effects of catecholamines [13, 22, 29–31].
Arrhythmias and thromboembolic events are
mostly seen in adult patients as complications but
may be also seen in childhood. Most of the patients
(75–100%) in pediatric studies have ECG abnormal-
ities [2, 3, 5, 7, 8, 13]. Despite an increase in the
number of studies, the previously high ventricular
tachycardia rate has noticeably fallen. The preva-
lence of WPW syndrome varies from study to study
but its association with Ebstein anomaly is signifi-
cant [2, 3, 7–13]. In our study, ECG findings were
initially abnormal in all but three patients. VT at-
tack and WPW pattern on Holter ECG were detec-
ted in one patient each. Three patients had symp-
tomatic bradycardia, and a permanent pacemaker
was implanted in one of them. After the implanta-
tion, complaints decreased and LV function im-
proved. Systemic emboli are another important
complication. Although their prevalence was as high
as 38% two decades ago, recent studies report it as
now being as low as 0–2% [2, 3, 7, 8, 13]. None of
our patients developed systemic emboli; only one
patient had been using long-term anticoagulants for
left-sided intracardiac thrombus. This decline in
incidence may be the result of early diagnosis, regu-
lar and short-interval follow-up and/or antiaggre-
gant or anticoagulant therapy.
Another interesting point is the association of
LVNC with dysmorphic features and neuromuscu-
lar diseases [2, 7, 32]. Twenty-nine percent of the
patients in our study had dysmorphic features and/
/or neurological findings, which led us to perform
metabolic screening of all our patients. Two pa-
tients with neurological involvement had fatty acid
oxidation disorder and mitochondrial disease, re-
spectively. This suggests that it is only necessary
to perform detailed metabolic screening for LVNC
patients with dysmorphic features, neurological in-
volvement or metabolic signs. In our study, three
patients had dysmorphic features, neuromotor re-
tardation and hydrocephalus, and one of them need-
ed ventriculoperitoneal shunting. Even though pre-
vious studies have reported the association of
LVNC with neurological signs, no study has repor-
ted the association between LVNC and hydrocepha-
lus. Further follow-up and examination is neces-
sary to clarify whether the association is coinciden-
tal or not.
Treatment of patients with LVNC should be
directed towards the three most important clinical
manifestations: CHF, arrhythmias, and systemic
embolic events [2, 27–29, 33]. Standard treatment
with inotropic support and preload and afterload re-
ducers should be started in patients with systolic
and diastolic ventricular dysfunction progressing to
CHF [2, 5, 7–13]. In addition to this, patients with
decreased systolic functions should be started on
beta-blockers (especially carvedilol), which have
been shown to improve LV and neurohormonal dys-
function in children [2, 5, 33, 34]. In addition to stan-
dard therapy, carvedilol was administered to 12 pa-
tients with CHF findings in our study. Continu-
ous Holter ECG should also be performed in all
patients due to increased risk of arrhythmias. All
patients should be started on aspirin to reduce and
prevent the risk of systemic embolic events. No
embolic events during follow-up have been report-
ed in patients who were on aspirin and being con-
tinuously monitored [2]. Similarly, all our patients
were started on aspirin and no thromboembolic
events occurred in the two year follow-up period in
any of them. Several authors recommend long-term
prophylactic anticoagulant therapy to patients with
LVNC, regardless of the presence of thrombi, but
standard procedure is to use low-molecular-weight
heparin or coumadine only if thrombi have been
detected [2, 8, 33, 35].
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Limitations of the study
Our study was performed in a tertiary center
and so the study group may not accurately repre-
sent the general population. The study was retro-
spective, so one must take into consideration the
relative shortness of the follow-up period and the
fact that no detailed genetic analysis was performed.
Treatment choices were made by the patients’ first
clinicians so the drug efficacy and the drugs’ effect
on complications could not be clarified. Long term
forward-looking studies with more patients are
needed to clarify these effects.
Conclusions
LVNC is a congenital cardiomyopathy with
variable clinical presentation. It can be diagnosed
at any point between the neonatal period and ado-
lescence. Although ECG abnormalities are frequent
in the pediatric population, arrhythmia and throm-
boembolic events are rare. If LVNC patients have
dysmorphic and abnormal neuromotor signs, de-
tailed neurological examination and metabolic tests
should be performed. Echocardiographic examina-
tion is the standard tool for diagnosis; however, the
physician performing the examination must be fa-
miliar with specific findings that point to LVNC, so
that any delay in diagnosis can be avoided. Cardiac
MR is the diagnostic tool to be used when diagno-
sis is uncertain. Since LVNC is an important rea-
son for morbidity and mortality, regular long-term
follow-up is absolutely required.
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